Pharmacoeconomics & Drug Compliance Dr Arif Hashmi.

Slides:



Advertisements
Similar presentations
What You Wanted to Know About Formularies Emmanuelle Mirsakov Pharm.D. Candidate 2007 USC School Of Pharmacy.
Advertisements

Management of Drug Formulary Dimitry Gotlinsky Western University Managed Care Clerkship ProPharma Pharmaceutical Consultants, Inc. 06/16/06.
CD Week 22: Patient compliance “An action in obedience to another request” COMPLIANCE IS A MAJOR HEALTH PROBLEM!
Introduction Medication non adherence ( noncompliance) remains a major problem. You have to assess and treat adherence related problems that can adversely.
1 Are you sure your improvements are cost-effective? Edward Broughton, PhD, MPH, PT University Research Co. April 11, 2014
Disease State Management The Pharmacist’s Role
Introduction to Pharmacoeconomics
MEDICINES SELECTION & FORMULARY MANAGEMENT
Copyright © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins Introduction to Clinical Pharmacology Chapter 04- The Nursing Process.
Lecture 3: Health Psychology and Physical Illnesses I (Part 2)
RATIONAL Prescribing & Prescription Writing Dr Arif Hashmi.
Drug Utilization Review (DUR)
A METHODOLOGY FOR MEASURING THE COST- UTILITY OF EARLY CHILDHOOD DEVELOPMENTAL INTERVENTIONS Quality of improved life opportunities (QILO)
Economic evaluation considers assessment of intervention effects in economic terms, which is often of greatest interest to fund allocators Intervention.
University of Southern California Department of Pharmaceutical Economics and Policy 1540 E. Alcazar Street, CHP 140 Los Angeles, CA
Patient Compliance With Medical Advice. Patient compliance (patient adherence) :  The extent to which the patient adheres to medical advice Patient compliance.
Drug and Therapeutics Committee
Budget Impact Analysis and Return on Investment Usa Chaikledkaew, Ph.D.
Do we need economics in medicine?. Edmund Burke, 1790 dcist.com/2007/12/10/revisiting_edmu.php “…the age of chivalry is gone. That of sophisters, economists,
Health Economics & Policy 3 rd Edition James W. Henderson Chapter 4 Economic Evaluation in Health Care.
Clinical Pharmacy Basma Y. Kentab MSc..
Clinical pharmacy Dr. Mohammed Al-Rekabi Lecture One First Semester.
Disease Management: High Risk Groups Principles in Practice Copyright © – Academy of Managed Care Pharmacy (AMCP)Slide 1.
1 Cost-effectiveness of improving medical services in low-resource settings Edward Broughton, PhD, MPH, PT University Research Co. May 21, 2014
Chapter 21: Adherence to Medical Regimens Alan M. Delamater Ashley Marchante Amber Daigre.
Continuous Quality Improvement Drug Utilization Evaluation.
PHAR 310: Pharmacoeconomics
Why are we learning this? How scientific knowledge (pharmacology, therapeutics) and clinical skills (measuring blood pressure, glucoses, drug information)
Following Your Treatment Plan. Taking your medication is an important part of your treatment. 2.
Pharmaceutical Economics Heng-Sim Lee RPh MS Director of Pharmacy, ChiaYi Branch, Taichung Veterans General Hospital Clinical Nutritional.
Social Pharmacy Lecture no. 8 Rational prescribing guidelines.
Basma Y. Kentab MSc.. 1. Define ambulatory care 2. Describe the value of ambulatory care practices 3. Explore pharmacy services in some ambulatory care.
Rational Prescribing & Prescription Writing Collected and Prepared By S.Bohlooli, Pharm.D, PhD.
 1. A care plan is developed for each of the patient's medical conditions being managed with pharmacotherapy.  2. A goal of therapy is the desired response.
Rational Use of Medicine Dr. Anjan Adhikari MBBS, MD, R G Kar Medical College Kolkata.
1 Care for Injection Drug Users (IDUs) with HIV HAIVN Havard Medical School AIDS Initiative in Vietnam.
Mohammad Aljawadi PharmD, PhD Clinical Pharmacy Department King Saud University PHCL 431 Sep, 2015.
انواع ارزيابي های اقتصادي سيدرضا مجدزاده مرکز تحقيقات بهره برداری از دانش سلامت و دانشکده بهداشت دانشگاه علوم پزشکي و خدمات بهداشتي درماني تهران.
Social Pharmacy Lecture no. 6 Rational use of drugs Dr. Padma GM Rao
PRINCIPLES OF DRUG ADDICTION TREATMENT Dr. K. S. NJUGUNA.
Why to study Pharmacoeconomics? Expansion of medical knowledge Increase in the treatment options Burden on the health care professionals to provide effective.
Determinants of Rational Use of Medicines Dr A K Sharma Prof & Head Dept of Pharmacology AFMC, Pune.
PHARMACOECONOMICS Dr. Mohammad Aljawadi, PharmD PhD Department of Clinical Pharmacy King Saud University Aug, 2015 PHCL 431.
Behavioral Science HEALTH BELIEF MODEL (HBM) Dr. G.U Ahsan, Ph.D.
Farid Abolhassani What is economic evaluation 16.
Why does SMC say NO We all want the most effective medicines All medicines cost money Health budgets are limited How do we choose?
Drug Formulary Development & Management
Presentation Developed for the Academy of Managed Care Pharmacy
Economic evaluation of health programmes Department of Epidemiology, Biostatistics and Occupational Health Class no. 7: Cost-effectiveness analysis – Part.
Given the progress that continues to be made in society’s battle against disease, patients are seeking more information about medical problems and potential.
Documentation in Practice Dept. of Clinical Pharmacy.
Chapter 14 Economic Analysis of Clinical and Managerial Interventions Copyright 2015 Health Administration Press.
Drug Utilization Review & Drug Utilization Evaluation: An Overview
PHARMACEUTICAL GUIDELINES: BASIC PRINCIPLES AND STATUTES.
Rational Use of Medication And Patient Compliance
HEALTH ECONOMICS BASICS
Prof. Md Sayedur Rahman Pharmacoeconomics: Bangladesh Perspective
DRUG PRESCRIBING.
Pharmaceutical Care Plan
Introduction to Clinical Pharmacy
Cost Effective Studies
Chapter Eleven: Management of Chronic Illness
Stevce Acevski PhD Alkaloid AD ISPOR Macedonia
Rational use of the drugs based on P-drug selection
Primum non nocere Olabisi Oshikanlu M.D., F.A.A.P
Pharmacy practice and the healthcare system Ola Ali Nassr
Pharmaceutical care plans Ola Ali Nassr
Introduction to Clinical Pharmacology Chapter 4 The Nursing Process
Presentation Developed for the Academy of Managed Care Pharmacy
Presentation transcript:

Pharmacoeconomics & Drug Compliance Dr Arif Hashmi

Objectives Explain pharmaco-economics & cost of prescription Evaluate the cost effective drug therapy. Discuss the concept of generic prescribing Discuss the significance of pharmaco-economics in various strata of society Explain drug compliance, adherence & therapeutic failure Discuss the consequences of noncompliance

What is Pharmacoeconomics? A branch of economics that uses cost-benefit, cost-effectiveness, cost-minimization, cost-of-illness and cost-utility analyses to compare pharmaceutical products and treatment strategies. Weighing the costs and benefits of option 1 with those of option 2 (for instance, a new drug and the previous best therapy) to determine which is the most efficient way to use our limited resources. Efficiency is a key concept in economics, i.e. how to buy the greatest amount of benefit for a given resource use.

Scarcity, choice and prioritisation The importance of Pharmacoeconomics can be found in;  Drugs to be included in formulary  Drugs showing maximum efficacy for a particular individual/patient  Drugs and services to be provided at different levels of healthcare to ensure most optimum outcome  Best drug for a particular disease  Improvement of quality of life of the patient by a particular therapy Scarcity of resources requires individuals to choose which goods and services they consume. The basis for their choice is the relative value that they place on each good or service. The structure of these relative values is the basis for their system of prioritisation.

What is QALY? Quality Adjusted Life Year (QALY) : attempts to integrate both quality and the quantity of life. QALY assumes that if a treatment increases one’s life expectancy by 2 years, but causes adverse effects or inconvenience, such that one’s quality of life or utility are decreased by 25%, the net gain is 2 x 0.75 = 1.5 QALYs.

METHODS in PE Analysis

What is cost effectiveness? Cost-effectiveness analysis compares the costs and health effects of an intervention to assess the extent to which it can be regarded as providing value for money. Cost–utility analysis the benefits are expressed as quality- adjusted life-years (QALYs) Cost–benefit analysis the benefits are expressed in monetary terms

What constitutes a cost? Costs are seen differently from different points of view. Direct costs, Indirect or productivity costs and Intangibles Direct costs: Medical: drugs; staff time; equipment Patient: transport; out-of pocket expenses Indirect costs: production losses; other uses of time (loss of work) Intangibles: pain; suffering; adverse effects.

GENERIC Prescribing Generic prescribing is the prescribing of a drug by a physician using the generic name. Paracetamol instead of Panadol

Generic substitution is based on the supposition that therapeutic equivalence, palatibility, and equivalent safety/adverse reactions exist among the various brands of a prescribed drug. Lowering of cost is the major factor in favor of generic prescribing. It is better to avoid generic prescribing in cases of drugs with low therapeutic indices.

PATIENT COMPLIANCE Compliance may be defined as "the extent to which the patients‘ behaviour coincides with medical or health advice.“ Reasonable to term a patient noncompliant when the failure to comply is sufficient to interfere appreciably with achieving the therapeutic goal.

Determinants of compliance THE ILLNESS: difficult to relate compliance patterns to particular diseases. Exception being patients with psychiatric illness, who are in general less compliant. In general, the longer the duration of treatment, the poorer is compliance likely to be. THE PATIENT: Education (better compliance), Social Status, Geriatric patients with polypharmacy (less compliant) THE DOCTOR: important influence on compliance (Number of drugs, patient communication, empathy)

MEASURING Compliance

IMPROVING Compliance By ensuring compliance: Single dose (gonorrhea), Depot formulations By removing bamers to compliance: Palatability of medicines can be improved (children) Blister calendar packs for oral contraceptives or 1 blockers help patients to remember to take the drug By simplifying therapeutic regimens reducing the number of tablets a patient has to take reducing the frequency of administration By educating the patient

THERAPEUTIC Failure Failure to accomplish the goals of treatment resulting from inadequate or inappropriate drug therapy and not related to the natural progression of disease. Multiple factors at different levels are involved; Non-Compliance Wrong or Inadequate Prescriptions Drug interactions unexplained

CONSEQUENCES of non - compliance Therapeutic failure Emergence of drug resistance Increased episodes of hospitalization Decreased QoL

THANK YOU